<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00228397</url>
  </required_header>
  <id_info>
    <org_study_id>3066A2-210</org_study_id>
    <nct_id>NCT00228397</nct_id>
  </id_info>
  <brief_title>Study Evaluating CCI-779 in Relapsing Multiple Sclerosis</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Long-term Extension Study to Determine the Safety, Tolerability, and Preliminary Efficacy of CCI-779 in Subjects With Relapsing Multiple Sclerosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of long-term therapy with 3 dose levels of oral
      CCI-779 administered to subjects with relapsing MS who completed study 3066A2-205-WW.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term safety.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Listing and summary tables of AE and TEAEs, vital signs, laboratory evaluations, and ECG data will be generated.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy of long-term treatment.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesions observed on MRI scans, clinical measures such as the EDSS scale, the 9-Hole Peg Test, the Paced Auditory Serial Addition Test and the Timed Ambulation 25-Foot Test, occurrence of relapse, will be analyzed at end -point (12 or 16 months).</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Only descriptive statistics will be performed.</measure>
  </secondary_outcome>
  <enrollment type="Actual">221</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCI-779</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with relapsing-remitting MS or secondary progressive MS with relapses.

          -  Successful completion of study 3066A2-205-WW with no major protocol violations.

        Exclusion Criteria:

          -  Pregnancy or lactation.

          -  Clinically important abnormalities on the physical examination, vital signs, or
             electrocardiogram (ECG) performed at the last visit of study 3066A2-205-WW (day 252).

          -  Any adverse events or findings observed in study 3066A2-205-WW that in the opinion of
             the investigators would preclude the subject's entry into the extension study.

        Please refer to section 16.2 'Discontinuation and Withdrawal of Subjects' regarding
        withdrawal of patients who have any clinical abnormalities in hematology or laboratory test
        results obtained at the last visit of the double-blind active phase of study 3066A2-205-WW.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2005</study_first_posted>
  <last_update_submitted>February 11, 2013</last_update_submitted>
  <last_update_submitted_qc>February 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2013</last_update_posted>
  <keyword>Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

